Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
Antimicrobial Agents and Chemotherapy
|
December 20, 2000
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy
O Lomovskaya, M S Warren, A Lee, et al.
Blood
|
August 23, 2022
Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies
Adam J Kanack, Curtis G Jones, Bandana Singh, et al.
Journal of Molecular Biology
|
October 20, 2019
Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease
Alexander Tischer, Maria A Brehm, Venkata R Machha, et al.
Nature Chemistry
|
August 1, 2018
Isolation, synthesis and bioactivity studies of phomactin terpenoids
Yusuke Kuroda, Karen J Nicacio, Ildefonso Alves da Silva-Jr, et al.
Blood
|
September 8, 2020
A prospective, blinded study of a PF4-dependent assay for HIT diagnosis
Bethany Samuelson Bannow, Deepti M Warad, Curtis G Jones, et al.
Molecular Cancer Therapeutics
|
August 14, 2020
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity <i>In Vitro</i> and <i>In Vivo</i>
Yamini M Ohol, Michael T Sun, Gene Cutler, et al.
American Journal of Hematology
|
May 2, 2026
Pathogenic PF4/Polyanion ELISA-Negative Antibodies in HIT
Adam J Kanack, Noah P Splinter, Emily E Mauch, et al.
Journal of Medicinal Chemistry
|
April 18, 2020
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity
Paul R Leger, Dennis X Hu, Berenger Biannic, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Pathogenic PF4/Polyvinylsulfonate ELISA-negative Antibodies in HIT
Adam J Kanack, Noah P Splinter, Emily E Mauch, et al.
Journal of Medicinal Chemistry
|
September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy
Jeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
Antimicrobial Agents and Chemotherapy
|
December 20, 2000
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy
O Lomovskaya, M S Warren, A Lee, et al.
Blood
|
August 23, 2022
Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies
Adam J Kanack, Curtis G Jones, Bandana Singh, et al.
Journal of Molecular Biology
|
October 20, 2019
Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease
Alexander Tischer, Maria A Brehm, Venkata R Machha, et al.
Nature Chemistry
|
August 1, 2018
Isolation, synthesis and bioactivity studies of phomactin terpenoids
Yusuke Kuroda, Karen J Nicacio, Ildefonso Alves da Silva-Jr, et al.
Blood
|
September 8, 2020
A prospective, blinded study of a PF4-dependent assay for HIT diagnosis
Bethany Samuelson Bannow, Deepti M Warad, Curtis G Jones, et al.
Molecular Cancer Therapeutics
|
August 14, 2020
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity <i>In Vitro</i> and <i>In Vivo</i>
Yamini M Ohol, Michael T Sun, Gene Cutler, et al.
American Journal of Hematology
|
May 2, 2026
Pathogenic PF4/Polyanion ELISA-Negative Antibodies in HIT
Adam J Kanack, Noah P Splinter, Emily E Mauch, et al.
Journal of Medicinal Chemistry
|
April 18, 2020
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity
Paul R Leger, Dennis X Hu, Berenger Biannic, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Pathogenic PF4/Polyvinylsulfonate ELISA-negative Antibodies in HIT
Adam J Kanack, Noah P Splinter, Emily E Mauch, et al.
Journal of Medicinal Chemistry
|
September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy
Jeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
Page
of 11